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Abstract The role of the neutral amino acid glycine in
excitotoxic neuronal injury is unclear. Glycine coactivates
glutamate N-methyl-D-aspartate (NMDA) receptors by
binding to a distinct recognition site on the NR1 subunit.
Purely excitatory glycine receptors composed of NR1 and
NR3/NR4 NMDA receptor subunits have recently been
described, raising the possibility of excitotoxic effects
mediated by glycine alone. We have previously shown that
exposure to high concentrations of glycine causes
extensive neurotoxicity in organotypic hippocampal slice
cultures by activation of NMDA receptors. In the present
study, we investigated further properties of in vitro
glycine-mediated toxicity. Agonists of the glycine recog-
nition site of NMDA receptors (D-serine and D-alanine)
did not have any toxic effect in hippocampal cultures,
whereas competitive blockade of the glycine site by 7-
chlorokynurenic acid was neuroprotective. Stimulation
(taurine, β-alanine) or inhibition (strychnine) of the
inhibitory strychnine-sensitive glycine receptors did not
produce any neurotoxicity. The toxic effects of high-dose
glycine were comparable in extent to those produced by
the excitatory amino acid glutamate in our model. When
combined with sublethal hypoxia/hypoglycemia, the
threshold of glycine toxicity was decreased to less than
1 mM, which corresponds to the range of concentrations
of excitatory amino acids measured during in vivo cerebral
ischemia. Taken together, these results further support the
assumption of an active role of glycine in excitotoxic
neuronal injury.
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Introduction
Excitatory amino acid-mediated toxicity has been recog-
nized as a major cause of neuronal cell death in different
neurologic diseases such as ischemia, epilepsy, and trauma
(Choi and Rothman 1990; Lipton and Rosenberg 1994).
Extracellular release of glutamate after acute brain injury
leads to uncontrolled activation of N-methyl-D-aspartate
(NMDA) receptors, intracellular penetration of calcium,
and initiation of deleterious processes finally leading to
cell death. The role of the neutral amino acid glycine in
excitotoxic neuronal injury is less clear. Under physiologic
conditions, glycine is a necessary coactivator of NMDA
receptors by binding a site distinct from the glutamate
recognition site and by allosterically promoting glutamate
activation of the NMDA-associated ion channel (Johnson
and Ascher 1987; Kleckner and Dingledine 1988; Thom-
son 1990; Dingledine et al. 1999; Foucaud et al. 2003).
Several older studies have reported that glycine alone may
be able to activate NMDA receptors in the absence of
glutamate or NMDA (Meguro et al. 1992; Kutsawada et
al. 1992; Pace et al. 1992). In a recent study using subunit
recombinant methods, glycine was found to fully and
exclusively activate NMDA receptors containing the NR3
subunit family (Chatterton et al. 2002). This suggests the
presence of functional excitatory glycine receptors in the
brain.
Abnormal elevations of glycine concentration accom-
panying that of excitatory amino acids have been reported
in several pathologic conditions, supporting the assump-
tion that glycine may also play a role in excitotoxic
neuronal injury (Perry and Hansen 1981; Larson and Beitz
1988; Globus et al. 1991a, 1991b; Kanthan and Shuaib
1995; Castillo et al. 1996; Saransaari and Oja 2001). In
acutely prepared hippocampal slices, exogenously applied
high concentrations of glycine caused electrophysiological
manifestations of excitotoxicity similar to the effects of
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glutamate (Wallis et al. 1995). Whole cell voltage-clamp
recordings of cultured rat hippocampal neurons showed
that high concentrations of glycine and other neutral
amino acids were able to elicit inward current responses by
activation of NMDA receptors (Pace et al. 1992). In a
previous study, we have found that high concentrations of
glycine (2–4 mM) caused hyperexcitability and subse-
quent neuronal cell death in rat organotypic hippocampal
slice cultures (Newell et al. 1997). These neurotoxic
effects occurred in all regions of the hippocampal cultures
but were most marked in area CA1. There was significant
CA1 neuronal damage in cultures exposed to 10 mM
glycine for 30 min or longer, or those exposed to 4 mM
glycine for 24 h. The NMDA antagonists MK-801 and
APV completely blocked glycine-induced neuronal de-
generation in all hippocampal subfields, suggesting
involvement of NMDA receptors. In contrast, a-amino-3-
hydroxy-5-methyl-4-isoxazoleprionic acid (AMPA) an-
tagonists such as CNQX, DNQX, or NBQX had no effect
on glycine-induced neuronal cell death.
The problem with this in vitro model of excitotoxicity is
that very high concentrations are needed to produce toxic
effects of glycine. From a strictly pharmacologic point of
view, it is debatable whether amounts of amino acids in the
millimolar range can have some relevance to explain
receptor-mediated excitotoxic mechanisms and whether
the observed lesions do not simply reflect an unspecific
metabolic challenge. In order to address this problem, and
to extend our previous results (Newell et al. 1997), we
investigated further properties of glycine-induced neuro-
toxicity in hippocampal slice cultures. In particular, we
were interested (a) to examine the effects of glycine site
NMDA agonists and antagonists on glycine toxicity, (b) to
study the possible involvement of strychnine-sensitive
glycine receptors, (c) to compare the toxic effects of
glycine with those of glutamate in our model, and (d) to
see whether combining glycine exposure with sublethal
hypoxia/hypoglycemia can decrease the threshold of
neurotoxicity below the millimolar range, which corre-
sponds to the concentrations of excitatory amino acids
encountered in in vivo models of cerebral ischemia.
Materials and methods
The methods of hippocampal slice preparation, exposure
to glycine, and cell death assessment have been described
in detail elsewhere (Newell et al. 1995a, 1995b, 1997). All
experiments and surgical procedures were approved by the
Animal Research Committee of the University of
Washington, Seattle, Wash., USA and complied with the
American legislation on animal care. Hippocampal slice
cultures were prepared from 5- to 7-day-old neonatal rats
(Sprague-Dawley, Bantin and Kingman Inc., Fremont,
Calif., USA) according to the method of Stoppini et al.
(1991) and grown on sterile transparent Anocel mem-
branes (Whatman Inc., Clifton, N.J., USA). The growth
medium consisted of 50% MEM (Gibco Laboratories,
Grand Island, N.Y., USA) supplemented with hydro-
xyethylpiperazine ethanesulfonic acid (HEPES) and sodi-
um bicarbonate, 25% Hank’s balanced salt solution
(HBSS), 25% horse serum, and glucose to a final
concentration of 6.5 mg/ml. The cultures were grown for
10–14 days before experimentation at 36.5°C, 90–100%
humidity, and 5% CO. Care was taken to select healthy
and morphologically intact slices prior to insult exposure.
All chemicals used in this study were purchased from
Sigma Chemical Co. (St. Louis, Mo., USA). Chemicals
were prepared as stock solutions in glucose-free HBSS
and added as small aliquots to fresh growth medium
containing the cultures to achieve the final concentrations
described. Propidium iodide (PI), which rapidly enters
cells with damaged membranes and becomes fluorescent
after binding to nucleic acids, was added (0.5 μg/ml) to the
culture medium as an indicator of neuronal cell death. The
cultures were then placed in the CO2 incubator at 36.5°C
for the described time intervals. Following insult exposure,
the cultures were replenished with fresh growth medium
with PI and returned to the incubator.
For exposure to oxygen and glucose deprivation,
cultures were rinsed three times in glucose-free HBSS
and then placed in HBSS without glucose. The temper-
ature of each individual culture well was maintained at 37°
C with an electronic thermometer. The cultures were then
transferred into an anaerobic chamber (Forma Scientific,
Marietta, Ohio, USA) pre-equilibrated to 37°C with an
atmosphere of 0% oxygen, 10% hydrogen, 5% CO2, and
85% nitrogen. The hydrogen was present for interaction
with a palladium catalyst that maintained the oxygen
concentration at 0%. An exposure of 20 min typically did
not produce visible damage to the control cultures and was
defined as sublethal exposure to ischemia. Upon removal
from the anaerobic chamber, the cultures were transferred
to prewarmed growth medium containing PI and placed in
a CO2 incubator at 36.5°C for 48 h.
For assessment of cell death, the cultures were
examined using a Nikon Diaphot inverted fluorescent
microscope. Fluorescent images were obtained using a
Dage 72 CCD camera (Michigan City, Ind., USA) and
were digitized using Optimas image analysis software
(Bio-Scan Inc., Edmonds, Wash., USA). The intensity of
PI fluorescence in the CA1 area was used as an index of
cell death. The first measurement of fluorescent intensity
was performed 40–48 h after initial exposure. The
remaining neurons were killed by exposing the cultures
to 3 h of anoxia. The fluorescent intensity obtained 24 h
after 3 h of anoxia was set equal to 100% damage and was
compared to the fluorescent intensity following the initial
insult. The integrated gray values (fluorescent intensity)
from CA1 following the initial insult were consequently
expressed as a percentage of the value obtained following
3 h of anoxia (complete damage). The values were
averaged for each group and expressed as mean±SEM.
Statistical analysis of the results was performed using the
Mann-Whitney test with Bonferroni correction for multi-
ple comparisons. Significant differences were considered
at P value <0.05.
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Results
To determine if glycine site agonists of NMDA receptors
were able to cause neurotoxicity, D-serine and D-alanine
were administered at high doses to hippocampal cultures.
In contrast to glycine’s toxic effects, exposure to 10 mM
D-serine or D-alanine did not produce any fluorescence
indicative of cell death in the cultures (Fig. 1a). Blockade
of NMDA receptor activation by administration of the
competitive glycine site antagonist 7-chlorokynurenic acid
(5 mM) completely protected the hippocampal cultures
against glycine toxicity (Fig. 1b). 7-chlorokynurenic acid
was as effective, although less potent, as MK-801 or APV
(Newell et al. 1997).
Modulation of the activity of strychnine-sensitive
inhibitory glycine receptors did not have any effect on
glycine-induced toxicity. Agonists of glycine on its
inhibitory receptor such as taurine or β-alanine did not
produce any toxicity up to 10 mM (Fig. 2a). Addition of
30 μM strychnine, by itself nontoxic to hippocampal
cultures, was unable to revert cell death caused by
exposure to 10 mM glycine (Fig. 2b). The observation
that glycine toxicity appeared to be mediated by NMDA
receptors opened the possibility that the observed effects
were not caused by glycine itself, but resulted from
secondary synaptic release of glutamate with subsequent
NMDA receptor overactivation. However, blockade of
synaptic activity by addition of tetrodotoxin (1 μM) did
not prevent complete cell death after exposure to high-
dose glycine, suggesting that this toxic effect was not
mediated by excitatory amino acid release (data not
shown).
Exposure of organotypic hippocampal cultures to
glutamate revealed a remarkable similarity with glycine-
induced toxicity, except for the fact that glutamate caused
global damage in the hippocampus without particular
vulnerability of area CA1, as noted for glycine (Newell et
Fig. 1 a Exposure of CA1 area to glycine and the glycine site
agonists D-serine and D-alanine (10 mM each) showed different
effects. Whereas glycine was highly neurotoxic, D-serine and D-
alanine did not produce any cell damage (*P<0.0001 compared to
controls, n=12 per group). b Neurotoxicity caused by exposure to
7.5 mM glycine could be completely blocked by the competitive
glycine site antagonist 7-chlorokynurenic acid (5 mM) (*P<0.0001
compared to controls, **P<0.0001 compared to glycine, n=12 per
group).
Fig. 2 a Exposure to the inhibitory glycine receptor agonists
taurine or β-alanine (10 mM each) did not cause any cell damage in
area CA1 (*P<0.0001 compared to controls, n=12 per group). b
Addition of 30 μM strychnine, by itself nontoxic to hippocampal
neurons, did not provide any protection against toxicity caused by
10 mM glycine (*P<0.0001 compared to controls, n=12 per group).
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al. 1997). Exposure to increasing doses of glutamate up to
10 mM showed that, as for glycine, cell death progres-
sively developed between 2 and 4 mM and was complete
at 8 mM (Fig. 3). In contrast to the complete blockade of
glycine toxicity achieved by NMDA receptor antagonists,
MK-801 (30 μM) only partially prevented neuronal
damage caused by glutamate exposure, supporting the
assumption that glutamate-induced toxicity is not only
mediated by NMDA, but also by non-NMDA receptors
(data not shown). Simultaneous exposure to increasing
concentrations of glycine and glutamate in different
combinations did not have any additive effect on neuro-
toxicity. Hippocampal cultures showed signs of cell death
developing at the same concentrations (2–4 mM) for both
compounds administered separately, supporting the possi-
bility of a comparable mediation of toxicity (Fig. 4).
To further address the problem of the apparently very
high concentrations needed to demonstrate glycine toxic-
ity, we were interested to recreate pathologic conditions in
our model and to observe their effects on the development
of glycine-induced cell death. We reproduced pathologic
ischemia-like conditions by exposing hippocampal cul-
tures to 20 min of oxygen and glucose deprivation (Newell
et al. 1995a, 1995b). Such an ischemia-like stress is not
lethal in our model as no PI fluorescence can be detected
in the cultures. When increasing doses of glycine or
glutamate were administered in combination with suble-
thal oxygen/glucose deprivation, we observed that neuro-
toxicity developed at significantly smaller concentrations
(<1 mM) than under normoxic/normoglycemic conditions
(Fig. 5).
Discussion
This study extends our previous results (Newell et al.
1997) by showing that glycine-induced neurotoxicity in
hippocampal slice cultures is a selective effect of glycine
not reproducible by glycine site agonists such as D-serine
and D-alanine. Complete inhibition of glycine toxicity by
7-chlorokynurenic acid confirms that functioning NMDA
receptors are necessary for glycine toxicity to develop.
Fig. 3 Comparison of the toxic effects produced by increasing
doses of glutamate and glycine in area CA1. The induced damage
showed a remarkable similarity between both amino acids with
toxicity developing at 2–4 mM and completing at 6–8 mM. No
significant difference was found between glycine and glutamate at
the different concentrations tested (*P>0.05 compared to glutamate
at the same concentration, n=9 per group).
Fig. 4 Different combinations of glycine and glutamate were
administered to hippocampal cultures to examine if glycine was able
to potentiate glutamate-induced neurotoxicity and vice versa. a
Concentrations of glycine and glutamate were simultaneously
increased from 1 to 8 mM. b Glutamate was increased from 1 to
8 mM in the presence of 1 mM glycine. c Glycine was increased
from 1 to 8 mM in the presence of a 1 mM glutamate. The results
showed that neurotoxicity developed between 2 and 4 mM and was
complete by 6–8 mM for all three protocols. No additive effect of
glycine on glutamate toxicity could be demonstrated (*P>0.05
compared between groups A, B, and C for the same concentration,
n=9 per group).
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Neuronal death caused by glycine does not appear to
involve strychnine-sensitive inhibitory glycine receptors.
In addition, as blockade of glutamate synaptic release by
tetrodotoxin did not reduce glycine toxicity, indirect
participation of excitatory amino acids is probably
excluded in our model. The comparability of glycine
toxicity with that produced by glutamate suggests that
glycine could be involved in certain neurologic disorders
in which neurotoxicity mediated by excitatory amino acid
plays a major role. This study also confirms that the
mechanisms of NMDA receptor activation/inhibition are
preserved in hippocampal slice cultures despite the very
high doses required to demonstrate glycine toxicity. We
assume that such supraphysiologic concentrations reflect
the retained efficacy of uptake mechanisms in hippocam-
pal cultures to remove and metabolize glycine from the
synaptic cleft (Newell et al. 1997). When glycine reuptake
was blocked by L-histidine, a small but distinct exacer-
bation of neurotoxicity was noted in our preparation (data
not shown). Under sublethal ischemia-like experimental
conditions, glycine- or glutamate-induced neurotoxicity
developed at concentrations below 1 mM, approaching the
concentrations of 200–300 μM measured during cerebral
ischemia in vivo (Globus et al. 1991a; Obrenovitch and
Richards, 1995). This effect probably resulted from a
blockade of glycine reuptake by oxygen/glucose depriva-
tion. It further supports the assumption that glycine may
play an active role in excitotoxic neuronal injury. It also
opens the possibility to study the mechanisms of glycine
toxicity using lower, more physiologic amino acid
concentrations than in the present study.
Glutamate NMDA receptors are ligand-gated ion
channels composed of at least four transmembrane sub-
units (NR1, NR2A-D, NR3A-B). NR1 always has to be
present to obtain a functional receptor. Different subunit
compositions, posttranscriptional modifications, as well as
links to intra- and extracellular signaling systems confer to
the receptor multiple modulation possibilities (Dingledine
et al. 1999; Cull-Candy et al. 2001). The binding site of
glycine is exclusively located on the NR1 subunit,
whereas the glutamate recognition site is on the NR2
subunit (Hirai et al. 1996; Foucaud et al. 2003). Glycine is
necessary to enable the glutamate-activated receptor to
adopt an open ion-channel configuration (Johnson and
Ascher 1987; Kleckner and Dingledine 1988; Thomson
1990; Dingledine et al. 1999). Complex interactions exist
between the two binding sites. Radioligand binding
studies have demonstrated that glutamate and glycine
reciprocally enhance the binding of the other ligand and
that binding of glutamate site antagonists is enhanced by
some glycine site antagonists and vice versa (Fadda et al.
1988; Monahan et al. 1990; Hood et al. 1990; Kaplita and
Ferkany 1990; McBain and Mayer 1994; Sucher et al.
1996). Full activation of NMDA receptors by glycine
alone seems to be possible under certain conditions
(Meguro et al. 1992; Kutsawada et al. 1992; Pace et al.
1992; Chatterton et al. 2002). Pace and colleagues
observed that high concentrations of neutral amino acids
such as glycine and L-serine (5 mM) can elicit inward
current responses in hippocampal neurons by activation of
NMDA receptors. L-serine currents were completely
blocked by the competitive NMDA antagonist CPP and
the CPP block could be overcome by increasing
concentrations of L-serine (Pace et al. 1992). In a recent
study on NR3A and NR3B subunits of NMDA receptors,
Chatterton et al. found that aggregations of these subunits
with NR1 were able to produce functional receptors fully
activated by glycine at physiologic concentrations of 3–
10 μM (Chatterton et al. 2002). D-serine, usually a
coagonist of conventional NMDA receptors, exerted an
antagonistic effect on these NMDA receptor subtypes,
particularly NR1/NR3A. Receptor activation did not
request the presence of glutamate or NMDA, leading
these authors to suggest that NR1/NR3A or −3B
heteromeres constitute a type of excitatory glycine
receptors. It is possible that overstimulation of such
excitatory glycine receptors can explain some neurotoxic
effects of glycine as described in the previous literature
and in our present study.
Several in vitro studies have demonstrated a participa-
tion of glycine in neuronal excitotoxic injury. Glycine has
been reported to markedly enhance neurotoxicity pro-
duced by NMDA in cortical cell cultures, presumably by
increased activation of NMDA receptors via their glycine
binding site (Shalaby et al. 1989; Patel et al. 1990;
McNamara and Dingledine 1990). Interestingly, McNa-
mara and Dingledine (1990) observed that very high
concentrations of glycine (up to 3 mM) potentiated
NMDA toxicity by a mechanism presumably independent
of glycine binding site activation. Although glycine alone
up to 1 mM was not toxic in this cortical cell culture
model, their findings have some similarity with our results.
Fig. 5 Comparison of neurotoxic effects of glycine and glutamate
under sublethal ischemia-like conditions. Hippocampal cultures
were exposed to sublethal oxygen/glucose deprivation (20 min) with
increasing doses of glycine or glutamate. Cell death assessment
showed that comparable neurotoxicity developed for glycine and
glutamate at smaller concentrations than under normoxic/normo-
glycemic conditions (<1 mM instead of typically 2–4 mM, see
Fig. 4), approaching the range of concentrations of excitatory amino
acids measured during in vivo cerebral ischemia (typically 200–
300 μM). This suggests that glycine can possibly contribute to
ischemic neuronal injury in a similar way to glutamate (*P>0.05
compared to glutamate at the same concentration, n=9 per group).
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First, the toxic potentiation effect of glycine necessitated
concentrations 50- to 100-fold higher than those required
to activate NMDA receptors. Second, selective agonists of
glycine binding site such as D-serine or D-alanine were
unable to potentiate NMDA toxicity, and third, glycine
potentiation was competitively blocked by APV and 7-
chlorokynurenic acid. Based on these findings, McNamara
and Dingledine suspected an effect of strychnine-sensitive
inhibitory glycine receptors. However, in the light of
recent knowledge, this effect could also be ascribed to
direct and full activation of certain glycine excitatory
receptors by glycine alone (Chatterton et al. 2002).
Glycine was shown to produce electrophysiological
signs of excitotoxicity similar to those of glutamate in a
model of acute hippocampal slices (Wallis et al. 1995).
Extracellular application of 10 mM glycine resulted in
excessive neuronal firing, followed by loss of neural
transmission and slow incomplete recovery. The electro-
physiological manifestations of glycine toxicity were only
partially blocked by NMDA receptor antagonists. In our
model using stabilized hippocampal slice cultures, the
mediation of glycine toxicity by NMDA receptors was
more evident and completely blocked by NMDA antago-
nists (Newell et al. 1997). In addition, our present results
also suggest that glycine can potentiate ischemic neuronal
injury in vitro.
Direct toxic effects of high extracellular glycine have
been more difficult to demonstrate in vivo than in vitro
(Obrenovitch and Richards 1995; Obrenovitch et al. 1997;
Shoham et al. 2001). Indirect evidence is supported by the
demonstration of pathologic elevations of glycine parallel-
ing that of excitatory amino acids in experimental
conditions such as cerebral ischemia (Graham et al.
1990; Globus et al. 1991a, 1991b; Baker et al. 1991;
Matsumoto et al. 1993; Obrenovitch and Richards 1995;
Saransaari and Oja 2001), hypoglycemia (Sandberg et al.
1986; Saransaari and Oja 2001), and head injury (Faden et
al. 1989). In an animal model subjecting rats to transient
global ischemia, glycine elevation persisted significantly
longer than that of glutamate, suggesting the possibility of
delayed toxicity in the course of stroke (Globus et al.
1991a, 1991b). Glycine is also assumed to be involved in
the initiation and spread of epileptic seizures (Larson and
Beitz 1988; Sierra-Paredes et al. 2001) and in the
pathogenesis of schizophrenia (Waziri and Baruah 1999).
Moreover, abnormal elevations of extracellular glycine
have been measured in different cerebral diseases where
uncontrolled release of excitatory amino acids is supposed
to play an important pathophysiologic role (Kanthan and
Shuaib 1995; von Essen et al. 1996; Castillo et al. 1996;
Castillo et al. 1997). However, despite these observations,
no clinical trial so far was able to demonstrate significant
outcome improvement by reducing NMDA receptor
activity with glutamate or glycine antagonists (Albers et
al. 1999; Lees et al. 2000; Ikonomidou and Turski 2002;
Madden 2002). In regard of the importance of excitotoxi-
city in human neurologic diseases, further research is
warranted in this field. It is hoped that new insights in the
biophysical and pharmacological properties of NMDA
receptors will enable better targeting of particular subunits
located in specific brain areas and open the way to new
therapeutic strategies (Cull-Candy et al. 2001).
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